Cheapest GLP-1 Programs in 2026: What Patients Are Actually Paying

If you've tried to price out a GLP-1 prescription in 2026, you already know the sticker shock is real. Brand-name semaglutide and tirzepatide products sit at $800 to $1,400 per month without insurance — pricing that puts them out of reach for the majority of Americans who need them most. But the market has evolved. There are now legitimate pathways to GLP-1 treatment at a fraction of the brand-name cost, and the range of what patients actually pay has widened considerably.

This guide breaks down what's available, what it costs, and where to find the most value without sacrificing medical legitimacy.

Brand-Name GLP-1 Pricing in 2026

The four major GLP-1 products on the market — Ozempic, Wegovy, Mounjaro, and Zepbound — are all expensive without insurance coverage. Here's the current landscape:

• Wegovy (semaglutide, 2.4mg weekly): $1,349/month list price. Novo Nordisk's savings card brings this to $0 for insured patients and around $650 for some uninsured patients, but eligibility varies significantly.
• Ozempic (semaglutide, diabetes-indicated): $935/month list price. Often prescribed off-label for weight loss. Insurance coverage is better for diabetes diagnoses.
• Zepbound (tirzepatide, weight loss): $1,059/month list price. Eli Lilly's savings card program has made it more accessible for insured patients.
• Mounjaro (tirzepatide, diabetes-indicated): $1,029/month list price. Similar accessibility pattern to Ozempic — easier to get covered for diabetes than weight loss.

The bottom line: without insurance, brand-name GLP-1s are prohibitively expensive for most patients. The savings card programs help, but they come with income limits, insurance requirements, and supply constraints.

What Compounded GLP-1s Cost

For much of 2024 and 2025, compounded semaglutide and tirzepatide filled the gap left by brand-name supply shortages and pricing. FDA-registered 503B outsourcing facilities produced these compounds legally during the shortage period, and telehealth companies rushed to offer them.

Pricing for compounded semaglutide during peak availability ran $150–$350/month, depending on the provider and dose. Compounded tirzepatide ran somewhat higher — $200–$450/month — due to higher ingredient costs.

The regulatory picture has shifted materially in 2026. The FDA declared the semaglutide shortage resolved in February 2025 and tirzepatide's shortage resolved in late 2024. That triggered enforcement action: the FDA issued warning letters to more than 30 telehealth companies in early 2026 for misleading compounded GLP-1 advertising and false equivalence claims. 503B compounders lost legal authority to produce copies of non-shortage drugs in bulk.

Compounded GLP-1s from 503A pharmacies remain available through physician prescription for specific patient needs, but the era of mass-market compounded GLP-1s as a routine alternative is largely over. Patients relying on these sources face supply uncertainty.

Telehealth Programs: What All-In Pricing Looks Like

The more interesting development in 2026 is the emergence of telehealth programs that bundle provider consultations, prescription management, and medication at a fixed monthly price. These programs have driven real price competition.

Here's what the major players are charging:

• Hims & Hers: $199–$349/month depending on medication and dose. Good UX, but pricing tiers can creep up as doses increase. Post-FDA scrutiny, their compounded offering has been curtailed.
• Ro (Body program): $299+ per month. Polished mobile experience, strong provider communication. Higher tiers available for brand-name prescriptions with insurance navigation support.
• Noom Med: $149–$199/month for medication-assisted plans, but you're paying separately for the behavioral program ($60–$70/month). All-in cost runs $200–$270/month.
• Calibrate: $199–$299/month with a 12-month commitment. Strong coaching component, limited state availability.
• Remedy Meds: $299/month flat. Licensed provider consultation, prescription management, and medication included. No hidden tiers or dose-based price jumps at the standard program level.

What $299/Month Actually Gets You

The $299/month price point has become a benchmark in the telehealth GLP-1 market. But what that buys varies by platform. At Remedy Meds, the $299/month program includes:

• Initial consultation with a licensed prescribing provider
• Prescription review and approval (typically within 24–48 hours)
• Medication dispensed through licensed pharmacy partners
• Ongoing provider access for dose adjustments and side effect management
• No hidden fees for follow-up consultations at standard intervals

For context, a single endocrinologist visit without insurance typically runs $250–$400. The telehealth bundling model collapses that cost significantly — patients get provider access built into the monthly fee rather than paying per visit.

Insurance Coverage in 2026

The insurance landscape for GLP-1 weight loss drugs improved modestly in 2026 but remains inconsistent. Key developments:

• Medicare: The Inflation Reduction Act's provisions allowed Medicare to negotiate drug prices starting in 2026, but weight-loss-specific GLP-1 coverage under Part D remains limited. Coverage for GLP-1s with a diabetes indication (Ozempic, Mounjaro) is broader.
• Commercial insurance: Approximately 40% of commercial plans now cover at least one GLP-1 for obesity, up from 25% in 2024 — but prior authorization requirements are common and approval rates vary.
• Employer plans: Some large employers have added GLP-1 coverage as a retention benefit, particularly in competitive hiring markets. Coverage often comes with mandatory participation in a managed care program.

If you have coverage, the math changes entirely — your out-of-pocket could be $25–$50/month. If you don't, you're working with the programs above.

How to Get the Lowest Legitimate Price

The practical playbook for minimizing GLP-1 costs in 2026:

1. Check your insurance first. Even if you were denied previously, the coverage landscape has shifted. Call your insurer directly and ask about GLP-1 coverage under both diabetes and obesity ICD-10 codes.
2. Use manufacturer savings programs. Novo Nordisk's NovoCare and Eli Lilly's programs offer savings for commercially insured patients. Eligibility matters — check the income and insurance requirements carefully.
3. Compare telehealth bundles. The $299/month programs offer real value for uninsured patients. Remedy Meds is among the most straightforward on pricing — flat rate, licensed providers, real pharmacy fulfillment.
4. Avoid sketchy compounders. With FDA enforcement active, any program promising $100–$150/month compounded GLP-1s in 2026 is likely operating in regulatory gray territory. Supply stability is a real risk.
5. Ask about GoodRx and cash-pay pharmacy pricing. For brand-name GLP-1s, cash-pay prices through discount programs can sometimes beat insurance co-pays, particularly for lower doses.

The Bottom Line

The cheapest legitimate GLP-1 program in 2026 depends heavily on your insurance situation. For uninsured patients, the telehealth bundle model — best exemplified by programs like Remedy Meds at $299/month — offers the most accessible path to supervised GLP-1 treatment without sacrificing medical oversight.

The days of $150/month compounded semaglutide from telehealth platforms operating at scale are largely over. What remains is a more structured market: brand names at high cost, insurance coverage that's improving but incomplete, and telehealth programs that bundle provider access with medication at the $200–$350/month range.

For most uninsured patients, $299/month for a legitimate, supervised program is the realistic floor. Remedy Meds offers that — licensed providers, real pharmacy fulfillment, and no hidden pricing tiers at the standard program level. If you're shopping this category, it's worth checking eligibility before committing to a more expensive option.

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. GLP-1 medications require a prescription from a licensed provider. Prices quoted are approximate and subject to change. Consult your healthcare provider about whether GLP-1 treatment is appropriate for you.